Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mycobacterium bovis is a slow-growing, aerobic, acid-fast bacterium whose attenuated form, primarily the Bacillus Calmette-Guérin (BCG) vaccine strain, is used globally to prevent tuberculosis and other mycobacterial infections. Attenuation was achieved through repeated subcultivation, resulting in the loss of the RD1 genomic region, reducing virulence while retaining immunogenicity. BCG works by stimulating the immune system to develop protective immunity against Mycobacterium tuberculosis. It is also used therapeutically for bladder cancer immunotherapy but has safety concerns such as risks of disseminated infection for the immunocompromised.
Live attenuated bacterium that stimulates the immune system to develop protective immunity against Mycobacterium tuberculosis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mycobacterium bovis (attenuated) (BCG).